Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

Phase 3Not Yet RecruitingNCT03244072

Jason Ahee, M.D.60,000 enrolled

Overview

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

60,000

Conditions

Endophthalmitis

Interventions

MoxifloxacinDRUG

Intracameral injection

PlaceboDRUG

intracameral injection

Eligibility

Sex: ALLMin age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * visually significant cataracts Exclusion Criteria: * allergy to fluoroquinolones, cobalamin (B12)

Locations (1)

Zion Eye Institute

St. George, Utah, United States

Outcomes

Primary Outcomes

Endophthalmitis after cataract surgery

Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.

Time frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively

Central Contacts

Jason Ahee, M.D.

CONTACT

435-862-9865 aheejason@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.